Col A · Reported: E = 0.029 — no OIG correction · no M
Col B · OIG 2025: E = 0.0829 (= 0.029 ÷ 0.35) · no M
Col C · OIG 2012: E = 0.2071 (= 0.029 ÷ 0.14) · no M
Col D · Aiken: (harm_B … harm_C) × 1.07 elasticity · no M
Col E · Suppression: low = Col D (1.0×) … high = Col D-high × M_suppress [THEORETICAL]
Col D band: low = OIG 2025 (÷0.35) × Aiken, high = OIG 2012 (÷0.14) × Aiken. Col E band: low = Col D floor (no suppression), high = Col D-high × ownership M_suppress.
- Annual Departures (V) = FTE × (turnover ÷ 100). NSI 2026 national average: 17.6%.
- Vacancy Patient-Days = V × D × PPD. Each vacancy generates D days of understaffing exposure with PPD patients absorbed per day. Defaults: 78 days, 0.5 pts/RN.
- Base NSE rate (E_base = 0.029). Murphy 2021 base 0.029/patient-day, adjusted by Griffiths 2019 aHR 1.03 per day below ward mean. VERIFY Irish cohort; US generalizability uncertain.
- OIG capture-rate correction — Cols B & C only. Fixes a measurement problem in the observation instrument (how many events were counted vs. occurred). B = ÷0.35 (OIG 2025); C = ÷0.14 (OIG 2012). Applied to event count, never to per-event cost.
- Staffing elasticity (E_elast = 1.07) — Cols D & E only. Aiken 2002 OR 1.07 per additional patient/nurse. An independent causal mechanism, kept in a separate variable from the OIG fix. Applied once, not compounded daily.
- Suppression multiplier (M_suppress) — Col E only, shown as a band. Its low end is the no-suppression floor (= Col D low, 1.0×); its high end is Col D-high × M_suppress for the selected ownership (NP / Public / Academic 1.0× · For-profit chain 2.5× · PE 4.3×). For nonprofit, Col E = Col D. CMDS Mechanism 7 predicts ownership-correlated reporting suppression; directionally supported by Kannan 2023 (PE acquisition: +25.4% HAC). THEORETICAL — values are constructs, not measured ratios.
- Replacement cost ($60,090). NSI 2026. Identical across all five tiers — measured regardless of reporting status or ownership.
| Study | Design | Finding | Application |
|---|---|---|---|
| Griffiths 2019BMJ Qual Saf · PMC6716358 | Longitudinal; N=138,133; NHS England | aHR 1.03 / day | Base daily elasticity (Col A) |
| Aiken 2002JAMA 288:1987 · PMID 12387650 | Cross-sectional; 168 hospitals; PA | OR 1.07 / pt | Elasticity factor (Cols D, E) |
| Needleman 2011NEJM 364:1037 · PMID 21410372 | Shift-level; N=197,961 admissions | 2–9% mortality | Range validation |
| Event | 2017 Base | 2025 Adj. | Exc. Mort. | LOS+ | Weight | Status |
|---|---|---|---|---|---|---|
| CLABSICentral line BSI · PSI 07 | $48,108 | $61,145 | 0.150 | 10.4d | 7.3% | BENCH |
| HAPI Stage 3–4Pressure injury · PSI 03 | $14,506 | $18,437 | 0.068 | 4.0d | 31.8% | BENCH |
| VTEVenous thromboembolism · PSI 12 | $17,367 | $22,073 | 0.031 | 3.6d | 18.2% | BENCH |
| CAUTICatheter-associated UTI · HAI | $13,793 | $17,531 | 0.014 | 2.4d | 20.0% | BENCH |
| Falls with InjuryJCC 2019 avg · AHRQ ~$6,694 all-falls | $14,056 | $17,865 | 0.026 | 6.3d | 7.3% | BENCH |
| HAPHospital-acquired pneumonia · PSI 11 | $40,144 | $51,023 | 0.118 | 7.9d | 6.4% | BENCH |
| IHCA / Failure to RescueDamluji 2018 · $35,808 (2012$) anchor | $35,808 | $45,000 | 0.764 | varies | 2.7% | DERIVED |
| ADE / Med ErrorAdverse drug event · AHRQ 2017 | $5,746 | $7,303 | 0.012 | 2.2d | 3.6% | BENCH |
| DeliriumLeslie 2008 · $16,303–$64,421 (2005$) | $35,000* | $35,000 | elev. | 2.5–10.4d | 2.7% | DERIVED |
| C_event · Weighted Average | — | $24,826 | — | — | 100% | DERIVED |
| Ownership Type | Est. Reporting Rate | M_suppress | Status |
|---|---|---|---|
| Private equity ownedContractual non-disclosure; cost extraction | 10–14% | 4.3× | THEORETICAL |
| For-profit corporate chainMargin pressure; risk-management protocols | 14–18% | 2.5× | THEORETICAL |
| Nonprofit, non-academicReputational protection; TJC risk mgmt | 16–20% | 1.0× | BENCHMARK |
| Nonprofit academic / publicResearch mission; stronger oversight | 20–28% | 1.0× | BENCHMARK |
| Safety net / public / CAHRegulatory scrutiny; union presence | 20–28% | 1.0× | BENCHMARK |
| NSI 2026$60,090/departure; 17.6% turnover; 78 days; 527 hospitals; 40 states; 262,405 RNs | BENCHMARKCOI: for-profit vendor; not peer-reviewed |
| AHRQ 2017HAC per-event costs; adjusted +27.1% CMS FY2025 MBI → 2025$ | BENCHMARK |
| OIG 2025 · OEI-06-18-0040135% confirmed capture rate — Col B denominator | VERIFIED |
| OIG 2012 · OEI-06-09-0009186% of events not reported; 14% capture — Col C denominator | VERIFIED |
| Aiken 2002 · JAMA 288:1987OR 1.07 per additional patient/nurse — Col D elasticity | VERIFIED |
| Griffiths 2019 · BMJ Qual SafaHR 1.03/day — base-rate adj. & sensitivity ceiling (1.03^78, §5B, non-primary); PMC6716358 | VERIFIED |
| Murphy 2021 · J Adv Nurs0.029 base NSE/patient-day; Irish cohort | VERIFY |
| Damluji 2018 · Circ Arrhythm EPIHCA $35,808/event (2012$); PHC uses $45,000 2025$ anchor | VERIFIED |
| Leslie 2008 · Arch Intern MedDelirium $16,303–$64,421 (2005$); PHC uses $35,000 anchor | VERIFIED |
| Kannan 2023 · JAMA Health ForumPE acquisition: +25.4% HAC, +27.3% falls, +37.7% CLABSI; PMC10751598 | VERIFIED |
| Spetz 2004 · J Nurs AdmAB 394 compliance $700K–$800K/hospital/yr | VERIFIED |
| BLS May 20243,391,000 employed RNs; median wage $93,600 | VERIFIED |
| HRSA 20252028 projected 3,034,360 RN FTE → 534,047 departures | BENCHMARK |
| JCC 2019 / Haines 2013Falls-with-injury avg $14,056 (pre-inflation); replaces AHRQ range midpoint | BENCHMARK |
| CMDS · Torrez 2026Suppression framework; doi:10.5281/zenodo.18985075 | THEORETICAL |
Five-tier architecture per the PHC Source-of-Truth Specification v1.3. Replacement & workforce: NSI 2026 [BENCHMARK]; BLS 2024 / HRSA 2025. Elasticity: Griffiths 2019, Aiken 2002, Needleman 2011 [VERIFIED]. Capture rates: OIG 2025 (35%) / OIG 2012 (14%) [VERIFIED]. C_event $24,826: 9-event composite (AHRQ 2017 + JCC 2019/Haines 2013 falls), normalized weights (110%->100%), +27.1% to 2025$ [DERIVED]. Cols D & E shown as a low–high band spanning the OIG 35%→14% capture range, each × Aiken 1.07 (primary elasticity). Griffiths daily-compound (1.03^78 = 10.03×) is a non-primary sensitivity ceiling [METHODOLOGICALLY AGGRESSIVE], shown only in Methodology §5B — never in primary output. Suppression: CMDS (Torrez 2026); Kannan 2023 [THEORETICAL].
Column E is a theoretical governance scenario; multiplier values are not measured reporting ratios. For litigation use, verify all component sources against primary documents before submission. Not legal or medical advice.
© 2026 Jennifer Torrez / PRISMqd. CC-BY 4.0. Cite as: Torrez J. (2026). Patient Harm Cost Calculator v3.4. PRISMqd Research Division.